Cargando…

Management of Huntington’s disease: role of tetrabenazine

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by progressive involuntary movements, neuropsychiatric disturbances, and cognitive impairment. The use of tetrabenazine (TBZ), a specific inhibitor of vesicular monoamine transporter, is approved for chorea i...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Tommaso, Marina, Serpino, Claudia, Sciruicchio, Vittorio
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071349/ https://www.ncbi.nlm.nih.gov/pubmed/21479143 http://dx.doi.org/10.2147/TCRM.S17152

Ejemplares similares

Tetrabenazine in the treatment of Huntington’s disease
por: Paleacu, Diana
Publicado: (2007)

Tetrabenazine is neuroprotective in Huntington's disease mice
por: Wang, Hongyu, et al.
Publicado: (2010)

Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
por: Claassen, Daniel O., et al.
Publicado: (2017)

Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease
por: Ferrara, Joseph M., et al.
Publicado: (2012)

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
por: Frank, Samuel
Publicado: (2010)

Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
por: Rodrigues, Filipe B., et al.
Publicado: (2017)

Laser Evoked Potentials in Early and Presymptomatic Huntington's Disease
por: de Tommaso, Marina, et al.
Publicado: (2016)

Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study
por: Frank, Samuel
Publicado: (2011)

Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
por: Frank, Samuel
Publicado: (2009)

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study
por: Dorsey, Ray, et al.
Publicado: (2011)

Clinical Assessment of the Effect of Tetrabenazine on Functional Scales in Huntington Disease: A Pilot Open Label Study
por: Fekete, Robert, et al.
Publicado: (2012)

Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease: A Retrospective Database Analysis
por: Claassen, Daniel O., et al.
Publicado: (2021)

Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
por: Rodrigues, Filipe B., et al.
Publicado: (2017)

Lower Prevalence of Chronic Pain in Manifest Huntington’s Disease: A Pilot Observational Study
por: Delussi, Marianna, et al.
Publicado: (2022)

Effects of high-frequency repetitive transcranial magnetic stimulation of primary motor cortex on laser-evoked potentials in migraine
por: de Tommaso, Marina, et al.
Publicado: (2010)

Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity
por: Paek, Seung-Mann
Publicado: (2020)

Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington’s and Other Diseases
por: Shen, Vivienne, et al.
Publicado: (2013)

Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington’s Disease–associated Chorea Initiated on Tetrabenazine
por: Sung, Victor W., et al.
Publicado: (2018)

Structural Mechanisms for VMAT2 inhibition by tetrabenazine
por: Dalton, Michael P., et al.
Publicado: (2023)

Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E
por: Sharma, Himanshu
Publicado: (2009)

Dual Treatment of Hemichorea–Hemiballismus Syndrome with Tetrabenazine and Chemodenervation
por: Umeh, Chizoba C., et al.
Publicado: (2012)

Behaviour of Tetrabenazine in Acid Medium: Reassessment and Impact on Formulation
por: Ettouati, Laurent, et al.
Publicado: (2019)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
por: Schneider, Frank, et al.
Publicado: (2020)

Clinical neurophysiology of chronic daily headache
por: de Tommaso, Marina, et al.
Publicado: (2000)

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine
por: Skor, Heather, et al.
Publicado: (2017)

Unique Case Reports of Tooth Sensitivity After Consuming Tetrabenazine
por: Daripa, Bob
Publicado: (2022)

P011. The use of electronic pain diaries via telemedicine for managing chronic pain
por: Franco, Giovanni, et al.
Publicado: (2015)

Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Enantioselective synthesis of (−)-tetrabenazine via continuous crystallization-induced diastereomer transformation
por: Kukor, Andrew J., et al.
Publicado: (2022)

Pediatric Migraine: Diagnosis and Management
por: Raieli, Vincenzo, et al.
Publicado: (2022)

A case of tics presenting as chronic intractable cough successfully treated with tetrabenazine
por: Pawar, Deepak G., et al.
Publicado: (2015)

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
por: Aguilar, Lourdes, et al.
Publicado: (2019)

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers
por: Schneider, Frank, et al.
Publicado: (2020)

Effective treatment of choreaballism due to an MT‐CYB variant with haloperidol, tetrabenazine, and antioxidants
por: Finsterer, Josef, et al.
Publicado: (2023)

Therapeutic Advances in the Management of Huntington’s Disease
por: Abdulrahman, Ganiy Opeyemi
Publicado: (2011)

Emerging Roles of Exosomes in Huntington’s Disease
por: Ananbeh, Hanadi, et al.
Publicado: (2021)

Juvenile Fibromyalgia and Headache Comorbidity in Children and Adolescents: A Literature Review
por: Matera, Emilia, et al.
Publicado: (2019)

Dysregulation of Corticostriatal Connectivity in Huntington’s Disease: A Role for Dopamine Modulation
por: Rangel-Barajas, Claudia, et al.
Publicado: (2016)

The Role of the Immune System in Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2013)

Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson
por: Tassone, Annalisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8494vajq8a0og693p8m6cgsbbb